Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 4/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | POLB | P06746 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | MITF | O75030 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.41 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.41 |
| ▸ | GRM5 | P41594 | 2/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12016065 | 0.81 | LMNA (0.46) | KCNH2MEN1KMT2ALMNACYP3A4 | |
| SCHEMBL10488162 | 0.81 | CYP3A4 (0.41) | KCNH2LMNACYP3A4CYP2C9CYP2D6 | |
| SCHEMBL25864597 | 0.81 | CYP3A4 (0.41) | KCNH2ALDH1A1MAPTLMNACYP3A4 | |
| SCHEMBL17729351 | 0.81 | APP (0.53) | KCNH2ALDH1A1MAPTCYP3A4CYP2C9 | |
| SCHEMBL29084200 | 0.81 | APP (0.53) | KCNH2CYP3A4CYP2C9CYP2D6CYP2C19 | |
| SCHEMBL12314517 | 0.81 | GRM5 (0.58) | KCNH2MEN1KMT2APOLBALDH1A1 | |
| SCHEMBL8349426 | 0.80 | CYP2C19 (0.52) | KCNH2MEN1KMT2APOLBALDH1A1 | |
| SCHEMBL19629593 | 0.79 | CYP2A6 (0.47) | KCNH2ALDH1A1CYP3A4CYP2C9CYP2D6 | |
| SCHEMBL19036905 | 0.78 | GRM5 (0.43) | KCNH2SMN1; SMN2L3MBTL1CYP3A4CYP2C9 | |
| SCHEMBL26775741 | 0.78 | RARB (0.44) | KCNH2ALDH1A1MAPTLMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3215510-B1 | SUBSTITUTED IMIDAZO[1,5-A]PYRIMIDINES AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | BIAL R&D INVEST S A (PT) | 2023-06-07 | — | — | EP | disclosed |
| US-11351173-B2 | Substituted pyrrolo[1,2-a]pyrimidines and their use in the treatment of medical disorders | Bial—R&D Investments, S.A. (PT) | 2022-06-07 | — | — | US | disclosed |
| US-20210309661-A1 | IMIDAZO[1,5-a]PYRIMIDINYL CARBOXAMIDE COMPOUNDS AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | BIAL - R&D INVESTMENTS, S.A. (PT) | 2021-10-07 | — | — | US | disclosed |
| US-20210177853-A1 | SUBSTITUTED PYRROLO[1,2-A]PYRIMIDINES AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | BIAL - R&D INVESTMENTS, S.A. (PT) | 2021-06-17 | — | — | US | disclosed |
| US-20210169886-A1 | SUBSTITUTED IMIDAZO[1,5-A]PYRIMIDINES AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | BIAL - R&D INVESTMENTS, S.A. (PT) | 2021-06-10 | — | — | US | disclosed |
| US-10787454-B2 | Imidazo[1,5-a]pyrimidinyl carboxamide compounds and their use in the treatment of medical disorders | BIAL—BioTech Investments, Inc. (PT) | 2020-09-29 | — | — | US | disclosed |
| EP-3215509-B1 | SUBSTITUTED PYRROLO[1,2-A]PYRIMIDINES AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | LYSOSOMAL THERAPEUTICS INC (US) | 2020-02-26 | — | — | EP | disclosed |
| US-20190119283-A1 | IMIDAZO[1,5-a]PYRIMIDINYL CARBOXAMIDE COMPOUNDS AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | BIAL - R&D INVESTMENTS, S.A. (PT) | 2019-04-25 | — | — | US | disclosed |
| US-20190112316-A1 | THIAZOLO[3,2-A] PYRIMIDINONE AND OTHER HETEROBICYCLIC PYRIMIDINONE COMPOUNDS FOR USE IN MEDICAL THERAPY | LYSOSOMAL THERAPEUTICS INC (US) | 2019-04-18 | — | — | US | disclosed |
| US-20180185368-A1 | SUBSTITUTED PYRROLO[1,2-A]PYRIMIDINES AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | LYSOSOMAL THERAPEUTICS INC. (US) | 2018-07-05 | — | — | US | disclosed |
| US-20170349598-A1 | PYRAZOLO[1,5-A]PYRIMIDINYL CARBOXAMIDE COMPOUNDS AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | BIAL - R&D INVESTMENTS, S.A. (PT) | 2017-12-07 | — | — | US | disclosed |
| US-20170349599-A1 | IMIDAZO[1,5-A]PYRIMIDINYL CARBOXAMIDE COMPOUNDS AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | BIAL - R&D INVESTMENTS, S.A. (PT) | 2017-12-07 | — | — | US | disclosed |
| US-20170334916-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIMIDINES AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | BIAL - R&D INVESTMENTS, S.A. (PT) | 2017-11-23 | — | — | US | disclosed |
| US-20170333435-A1 | SUBSTITUTED IMIDAZO[1,5-A]PYRIMIDINES AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | BIAL - BIOTECH INVESTMENTS, INC. (PT) | 2017-11-23 | — | — | US | disclosed |
| WO-2017192841-A1 | METHODS OF TREATMENT AND COMBINATION THERAPIES USING GCASE ACTIVATOR HETEROBICYCLIC AND RELATED COMPOUNDS | LYSOSOMAL THERAPEUTICS INC. (US) | 2017-11-09 | — | — | WO | disclosed |
| WO-2017161137-A1 | METHODS AND COMPOSITIONS FOR TREATING A NEURODEGENERATIVE DISORDER IN A SPHINGOTYPED SUBJECT | LYSOSOMAL THERAPEUTICS INC. (US) | 2017-09-21 | — | — | WO | disclosed |
| US-9732089-B2 | Substituted pyrazolo[1,5-a]pyrimidines and their use in the treatment of medical disorders | LYSOSOMAL THERAPEUTICS INC. (US) | 2017-08-15 | — | — | US | disclosed |
| US-20170183354-A1 | SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINES AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | BIAL - R&D INVESTMENTS, S.A. (PT) | 2017-06-29 | — | — | US | disclosed |
| WO-2017040879-A1 | THIAZOLO(3,2-A) PYRIMIDINONE AND OTHER HETEROBICYCLIC PYRIMIDINONE COMPOUNDS FOR USE IN MEDICAL THERAPY | LYSOSOMAL THERAPEUTICS INC. (US) | 2017-03-09 | — | — | WO | disclosed |
| WO-2017040877-A1 | HETEROBICYCLIC PYRIMIDINONE COMPOUNDS AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | LYSOSOMAL THERAPEUTICS INC. (US) | 2017-03-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190119283-A1 | IMIDAZO[1,5-a]PYRIMIDINYL CARBOXAMIDE COMPOUNDS AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | GBA1, GAA, GBA2 | KCNH2 2726/4885MEN1 1938/4885KMT2A 290/4885 |
| US-10787454-B2 | Imidazo[1,5-a]pyrimidinyl carboxamide compounds and their use in the treatment of medical disorders | GBA1, GAA, GBA2 | KCNH2 2726/4885MEN1 1938/4885KMT2A 290/4885 |
| US-20170334916-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIMIDINES AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | PARK7, PNP, GAA | KCNH2 3280/4885MEN1 3247/4885KMT2A 1241/4885 |
| US-20170333435-A1 | SUBSTITUTED IMIDAZO[1,5-A]PYRIMIDINES AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | GAA, GBA1, PARK7 | KCNH2 3679/4885MEN1 3116/4885KMT2A 598/4885 |
| US-11351173-B2 | Substituted pyrrolo[1,2-a]pyrimidines and their use in the treatment of medical disorders | TYMP, PARK7, PNP | KCNH2 4221/4885MEN1 3196/4885KMT2A 771/4885 |
| US-20210177853-A1 | SUBSTITUTED PYRROLO[1,2-A]PYRIMIDINES AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | TYMP, PARK7, PNP | KCNH2 4221/4885MEN1 3196/4885KMT2A 771/4885 |
| US-20190112316-A1 | THIAZOLO[3,2-A] PYRIMIDINONE AND OTHER HETEROBICYCLIC PYRIMIDINONE COMPOUNDS FOR USE IN MEDICAL THERAPY | PARK7, GAA, TYMP | KCNH2 3480/4885MEN1 2425/4885KMT2A 632/4885 |
| US-20170349598-A1 | PYRAZOLO[1,5-A]PYRIMIDINYL CARBOXAMIDE COMPOUNDS AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | GBA1, GAA, PARK7 | KCNH2 2443/4885MEN1 2082/4885KMT2A 607/4885 |
| US-20170183354-A1 | SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINES AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | PNP, PNPO, TYMP | KCNH2 4272/4885MEN1 3040/4885KMT2A 2215/4885 |
| US-20210169886-A1 | SUBSTITUTED IMIDAZO[1,5-A]PYRIMIDINES AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | GBA1, GAA, SNCA | KCNH2 3648/4885MEN1 2957/4885KMT2A 612/4885 |
| US-20180185368-A1 | SUBSTITUTED PYRROLO[1,2-A]PYRIMIDINES AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | TYMP, PARK7, PNP | KCNH2 4221/4885MEN1 3196/4885KMT2A 771/4885 |
| US-20170349599-A1 | IMIDAZO[1,5-A]PYRIMIDINYL CARBOXAMIDE COMPOUNDS AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | GBA1, GAA, GBA2 | KCNH2 2726/4885MEN1 1938/4885KMT2A 290/4885 |
| US-20210309661-A1 | IMIDAZO[1,5-a]PYRIMIDINYL CARBOXAMIDE COMPOUNDS AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | GBA1, GAA, GBA2 | KCNH2 2726/4885MEN1 1938/4885KMT2A 290/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.